On Monday, BridgeBio Pharma Inc (NASDAQ: BBIO) opened higher 7.05% from the last session, before settling in for the closing price of $34.77. Price fluctuations for BBIO have ranged from $21.62 to $39.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 574.82% over the last five years. Company’s average yearly earnings per share was noted -31.07% at the time writing. With a float of $155.49 million, this company’s outstanding shares have now reached $190.04 million.
The firm has a total of 730 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.67%, operating margin of -265.69%, and the pretax margin is -244.34%.
BridgeBio Pharma Inc (BBIO) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BridgeBio Pharma Inc is 18.25%, while institutional ownership is 76.09%. The most recent insider transaction that took place on Mar 06 ’25, was worth 419,500. In this transaction Director of this company sold 12,875 shares at a rate of $32.58, taking the stock ownership to the 1,764 shares. Before that another transaction happened on Mar 05 ’25, when Company’s 10% Owner sold 6,000,000 for $32.96, making the entire transaction worth $197,760,000. This insider now owns 19,260,971 shares in total.
BridgeBio Pharma Inc (BBIO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -31.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 45.40% during the next five years compared to -3.04% drop over the previous five years of trading.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Check out the current performance indicators for BridgeBio Pharma Inc (BBIO). In the past quarter, the stock posted a quick ratio of 4.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 31.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.85, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -2.72 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Analysing the last 5-days average volume posted by the [BridgeBio Pharma Inc, BBIO], we can find that recorded value of 2.92 million was lower than the volume posted last year of 3.14 million. As of the previous 9 days, the stock’s Stochastic %D was 87.69%. Additionally, its Average True Range was 1.81.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 87.32%, which indicates a significant decrease from 90.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.18% in the past 14 days, which was lower than the 62.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.03, while its 200-day Moving Average is $28.16. Now, the first resistance to watch is $38.51. This is followed by the second major resistance level at $39.79. The third major resistance level sits at $41.65. If the price goes on to break the first support level at $35.37, it is likely to go to the next support level at $33.51. Now, if the price goes above the second support level, the third support stands at $32.23.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
There are currently 190,189K shares outstanding in the company with a market cap of 7.08 billion. Presently, the company’s annual sales total 221,900 K according to its annual income of -535,760 K. Last quarter, the company’s sales amounted to 5,880 K and its income totaled -265,050 K.
